Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Chronic hepatitis C has become an endemic disease in Egypt with a rising prevalence (genotype
4), worldwide it also poses a significant health burden. To date standard of care treatment
(pegylated interferon and ribavirin) give modest results with a sustained virological
response (SVR) of about 50%. Several pharmaceutical and herbal agents have been used with an
aim to improve current results. Recent reports have suggested an increased SVR with the
addition of Nitazoxanide to standard of care. The results are preliminary and need to be
confirmed. This is a randomized trial to assess the efficacy of nitazoxanide added to
standard of care compared to standard of care alone.